NEWSLETTER

By clicking submit, you agree to share your email address with TFN to receive marketing, updates, and other emails from the site owner. Use the unsubscribe link in the emails to opt out at any time.

DeepMind spinout Isomorphic Labs lands $5B Series C to take AI-designed medicines into the clinic

Isomorphic Labs
Image credits: Isomorphic Labs
  • Isomorphic Labs has raised $5B in a Series C co-led by Greenoaks and Sequoia.
  • Bloomberg reported a valuation of about $50B; Isomorphic did not disclose one.
  • The cash funds IsoDDE and moves its first drug candidates towards clinical trials.

Isomorphic Labs has raised $5 billion in an oversubscribed Series C round, six months after its $2.1 billion Series B. The London-based AI drug discovery company was founded by Sir Demis Hassabis, who is also CEO of Google DeepMind. The financing was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz (a16z) and several other new investors.

Alphabet made a significant investment, and all existing investors took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. Isomorphic did not disclose a valuation. 

Bloomberg reported on November 4 that the company was in talks to raise about $5 billion at roughly $50 billion, up from the $40 billion or more TFN reported in October.

The latest round follows the company’s $2.1 billion Series B in May 2026, which was led by Thrive Capital, and its $600 million first external round in March 2025. Together, TFN calculates, that takes external funding to about $7.7 billion.

AI engine for drug discovery

At the centre of Isomorphic’s strategy is its Isomorphic Drug Design Engine (IsoDDE), a proprietary platform that combines foundational simulation models to predict and understand complex biological interactions.

Rather than focusing on a single disease area or drug type, IsoDDE is designed to work across multiple therapeutic areas and drug modalities. It explores vast chemical spaces to help researchers identify and refine molecules with desirable drug-like properties.

The company combines these models with AI agents that can reason across complex biological systems. Together, the technologies aim to improve the accuracy of predictions and help scientists design molecules with greater precision.

The ambition builds on DeepMind’s AlphaFold work on protein structure prediction. Isomorphic develops medicines in-house and with partners including Eli Lilly, Novartis and Johnson & Johnson. Hassabis told Bloomberg the company has more than 20 programmes under way, according to The Next Web.

From simulation to potential medicines

The company reports positive preclinical results from internal programmes in oncology and immunology, as well as work with pharmaceutical partners. Its next priority is to advance selected candidates towards clinical trials.

“When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI,” said Sir Demis Hassabis, founder and CEO of Isomorphic Labs.

“Our drug design engine is generating molecules with unprecedented precision and speed. This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients,” he added. 

In January, Hassabis said Isomorphic expected its first clinical trials by the end of 2026. 

Competition in AI-led drug discovery

Isomorphic operates in a fast-growing field where AI companies are attempting to redesign how medicines are discovered. San Francisco’s Chai Discovery, founded in 2024, raised $400 million at a $3.8 billion valuation in July and says Eli Lilly, Pfizer and Novartis have started adopting its models. Xaira Therapeutics launched in April 2024 with more than $1 billion. London-based Basecamp Research raised a $140 million Series C at an $800 million valuation in September, according to Reuters.

Isomorphic’s distinguishing strategy is its combination of foundational simulation models, AI agents and an expanding pipeline of its own therapeutic candidates.

The market behind them is growing quickly. According to MarketsandMarkets, the global AI in drug discovery market is projected to grow from $5.09 billion in 2026 to $17.56 billion by 2031, a compound annual growth rate of 28.1%.

Scaling towards clinical development

The Series C will fund further research into advanced biology models, expansion of the company’s partner ecosystem and development of global AI-led bioengineering infrastructure. Isomorphic also plans to build scalable AI-first translational and clinical development capabilities as its candidates move towards human testing. 

“Discovering and developing new medicines is an optimization challenge of almost infinite scale,” said Neil Mehta, founder and managing partner of Greenoaks. 

“Isomorphic is transforming that journey, building deep learning systems that can predict complex biological behaviors with remarkable accuracy and systematically map the path to new medicine,” added Konstantine Buhler, partner at Sequoia Capital. 

Can Isomorphic’s candidates show real benefit to patients in clinical trials, and on a timeline that justifies a reported $50 billion price tag?

Total
0
Shares
Related Posts
Total
0
Share
tfn-logo-2-220x220-removebg-preview

Get daily funding news briefings in the tech world delivered right to your inbox.

Enter Your Email
join our newsletter. thank you
TFN Banner